Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 7, 2008, Pages 686-696

  Haukka, Jari ^a   Tiihonen, Jari ^b   Härkänen, Tommi ^a   Lönnqvist, Jouko ^a,c  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antidepressives; Antipsychotics; Attempted suicide; Suicide

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOZAPINE; FLUOXETINE; HALOPERIDOL; MIANSERIN; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; SERTRALINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; DISEASE ASSOCIATION; DRUG USE; FEMALE; FINLAND; HOSPITALIZATION; HUMAN; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BAYES THEOREM; BENZODIAZEPINES; CITALOPRAM; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FINLAND; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SCHIZOPHRENIA; SUICIDE; SUICIDE, ATTEMPTED;

EID: 48249105115     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1579     Document Type: Article

References (33)

1. Nordentoft M, Laursen TM, Agerbo E, Qin P, Høyer EH, Mortensen PB. Change in suicide rates for patients with schizophrenia in Denmark, 1981-97: nested case-control study. Br Med J 2004; 329(7460): 261.
2. Heilä H, Haukka J, Suvisaari J, Lönnqvist J. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 2005; 35(5): 725-732.
3. Qin PN, Nordentoft M. Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers. Arch Gen Psychiatry 2005; 62(4): 427-432.
4. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005; 62(3): 247-253.
5. Saha S, Chant D, Welham J, Mcgrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2(5): e141.
6. Lieberman J, Stpoup TS, Mcevoy JP, et al. Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1286-1288.
7. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152(2): 183-190.
8. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8(6): 671-677.
9. Meltzer HY, Alps L, Green AI, et al. & Group. International Suicide Prevention Trial Study. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60(1): 82-91.
10. Tiihonen J, Walhbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Br Med J 2006; 333(7561): 224-229.
11. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001; 158(9): 1449-1454.
12. Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991; 17(4): 649-657.
13. Baynes D, Mulholland C, Cooper SJ, et al. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res 2000; 45(1-2): 47-56.
14. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med 2003; 33(4): 589-599.
15. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000; 57(4): 311-317.
16. Gunnell D, Sapenia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. Br Med J 2005; 330(7488): 385.
17. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. Br Med J 2005; 330: 396.
18. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 2006; 63(8): 865-872.
19. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163(1): 41-47.
20. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide and overall mortality in a nation-wide cohort. Arch Gen Psychiatry 2006; 63: 1358-1367.
21. Mäkikyrö T, Isohanni M, Moring J, Hakko H, Hovatta I, Lönnqvist J. Accuracy of register-based schizophrenia diagnoses in a genetic study. Eur Psychiatry 1998; 13: 57-62.
22. Suvisaari JM, Haukka JK, Tanskanen AJ, Lönnqvist J. Decline in the incidence of schizophrenia in Finnish cohort born from 1954-1965. Arch Gen Psychiatry 1999; 56: 733-740.
23. Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish hospital discharge register and causes of death register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12(2): 132-137.
24. WHO. http://www.whocc.no/atcddd/ [Accessed 22-05-2006].
25. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius A, de Boer A. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol 2001; 54(11): 1181-1186.
26. Skrbo A, Zulic I, Hadzi S, Gaon ID. Anatomic-therapeutic-chemical classification of drugs. Med Arh 1999; 53 (3 Suppl 3): 57-60.
27. Andersen PK, Borgan Ø, Gill RD, Keiding N. Statistical Models Based on Counting Processes. Springer-Verlag: New York, 1993.
28. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127 (8 Pt 2): 757-763.
29. Arjas E, Gasparra D. Nonparametric Bayesian inference from right censored survival data, using the Gibbs sampler. Statist Sinica 1994; 4: 505-524.
30. Raftery AL, Lewis S. Comment: one long run with diagnostics: implementation strategies for Markov Chain Monte Carlo. Stat Sci 1992; 7: 493-497.
31. R Development Core Team. R: a language and environment for statistical computing. In Vienna, Austria: R Foundation For Statistical Computing, 2004.
32. Härkänen T. BITE: a Bayesian intensity estimator. Comput Stat 2003; 18: 565-583.
33. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59(5): 437-447.